Vasculitis & polymyalgia rheumatica

Epidemiology and treatment outcome of ANCA-associated vasculitis in South Korea: a nationwide, population-based cohort study

Clin Exp RheumatolPublished Population-based cohort study

Authors' conclusion

In South Korea, the incidence of MPA has increased over time. Although both GPA and MPA had high rates of mortality and morbidity, MPA has a poorer prognosis than GPA.

Study context

Population
Entire Korean population, Korean National Health Insurance Service database and Rare Intractable Disease registry, 2010–2018
Exposure
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) vs matched general-population comparator
  • GPAn = 546
  • MPAn = 795
Outcome
Incidence and prevalence rates of GPA and MPA and trends over time
Methodological detailsnationwide, matched comparator (nearest-neighbour by age, sex, income and comorbidity index, 5:1)
  • Nationwide
  • Matched comparator (nearest-neighbour by age, sex, income and comorbidity index, 5:1)

Main finding

As reported in the abstract

Incidence of GPA and MPA · 2010-2018
  • Incidence of both diseases increased with age, peak among patients aged ≥70 years
  • Incidence of MPA increased continuously over time; GPA showed no significant changes

Observational data: associations, not effects.

Further findings

OutcomeGPAMPAHR
Mortality during observation periodGPA vs Comparator28.7%41.1%4.02
Standardised mortality ratio vs general population3.535.58
Mortality during observation periodMPA vs Comparator5.64

Mortality and morbidity (renal replacement therapy, ICU admission), MPA vs GPA

Higher mortality and morbidity rates in MPA than in GPA

Original publication

Epidemiology and treatment outcome of ANCA-associated vasculitis in South Korea: a nationwide, population-based cohort study. Clin Exp Rheumatol. Published 26 December 2023. doi:10.55563/clinexprheumatol/tqndi5

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.